FiercePharmaOriginal article
{"a":[{"_":"Peptide adcomm Day 2: Emideltide voted down in panel's 1st pushback","$":{"href":"/pharma/peptide-adcomm-day-2-emideltide-voted-down-panels-1st-peptide-pushback","hreflang":"en"}}]}
AdComrejectedEmideltideNegative
AI Analysis
Summary
An FDA advisory committee voted down emideltide on day two of discussions about adding unapproved peptides to the U.S. bulk compounding list, marking the panel's first negative vote on a peptide candidate.
Outcome Details
Emideltide voted down in panel's first pushback regarding bulk compounding list addition
Importance:6/10
Sentiment:
-0.70
peptidesbulk compoundingFDAadvisory committeeregulatory setback
Related Companies
Read the original article
Published by FiercePharma on July 24, 2026 12:13 PM